Actos Comes Out Clear In Second Bladder Cancer Risk Study
This article was originally published in PharmAsia News
Executive Summary
A now completed large-scale postmarketing study for Takeda's Actos has concluded that there is no association between the use of the diabetes drug and the risk of bladder cancer, although a previously agreed financial settlement of legal cases will go ahead.